Selection of target proteins for PROTAC can be based on the following considerations: 1. Whether the protein is specific or not, non-specific proteins can cause off-target toxicity; 2. Whether the protein belongs to the molecules that can be degraded by PROTAC, and it has been reported that the targets that can be used for PROTAC include, kinases (MEK, KRAS, CDK, and Bcr/Abl), transcription factors (e.g. p53, STAT, RAR, ER, and AR), epigenetic factors (e.g., HDAC and BET bromodomain), and E3 ligases themselves (e.g., MDM2), among others; 3. Whether or not the protein has been reported to have a ligand or crystalline form that can be commercially engineered.
产品编号 | 产品名称 | |
---|---|---|
T17996 | VH032-PEG5-C6-Cl | VH032-PEG5-C6-Cl (HaloPROTAC 2) is a small molecule HaloPROTAC that incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1]. |
T18632 | PROTAC MDM2 Degrader-2 | PROTAC MDM2 Degrader-2 is a compound designed utilizing PROTAC technology, functioning as a MDM2 degrader. Comprised of a highly potent inhibitor targeting MDM2, a linker, and the MDM2 ligand for E3 ubiquitin ligase, this compound facilitates the degradation of MDM2[1]. |
T17995 | Halo PROTAC 1 | Halo PROTAC 1 is a PROTAC, which is a ligand having activity to bind to an intracellular proteins fused with HaloTag and a structure having activity to induce autophagy of an intracellular molecule are linked via a PEG linker[1]. |
T5439 | BRD4 degrader AT1 | BRD4 degrader AT1 是基于 PROTAC 技术的高选择性 Brd4 降解剂,在细胞中对 Brd4BD2 的 Kd 为 44 nM。 |
T10875 | CP5V | CP5V, a PROTAC, induces mitotic inhibition, and suppresses cancer cell proliferation. It specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. |
T18598 | PROTAC BRD2/BRD4 degrader-1 | PROTAC BRD2/BRD4 degrader-1 (compound 15) serves as a potent, selective degrader of BET proteins BRD4 and BRD2, achieving rapid, reversible, and unexpectedly selective elimination of BRD4 and BRD2 compared to BRD3. Its efficacy in suppressing solid tumors manifest with minimal cytotoxic effects. This compound comprises a BET inhibitor, a connecting linker, and thalidomide as the ligand for cereblon (CRBN)/cullin 4A[1]. |
T13685 | ERD-308 | ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively).ERD-308 is a highly potent PROTAC degrade |
T11441 | GNE-987 | GNE-987 is a highly active chimeric BET degrader. GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50: 4.7 and 4.4 nM, respectively). GNE-987 exhibits picomolar cell BRD4 degradation activity (DC50: 0.03 |
T18682 | SJFδ | SJFδ is a 10-atom linker PROTAC that selectively degrades p38δ with a DC50 of 46.17 nM, without degrading p38α, p38β, or p38γ[1]. |
T18061 | KB02-SLF | KB02-SLF is a PROTAC-based nuclear FKBP12 degrader, known as a molecular glue. It facilitates the degradation of nuclear FKBP12 by covalently modifying DCAF16, an E3 ligase. Moreover, KB02-SLF enhances the longevity of protein degradation in biological systems. The compound SLF acts as a linker, binding to the ubiquitin E3 ligase ligand KB02, resulting in the formation of KB02-SLF[1]. |
T13552 | ARD-266 | ARD-266 is a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader, effectively inducing AR protein degradation in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s: 0.2-1 nM). |
T41180 | JQAD1 | JQAD1是一种有效的、选择性的组蛋白乙酰转移酶 EP300降解剂(PROTAC;DC50≤31.6nM);其包含 EP300抑制剂A485,通过连接体连接至脑啡肽E3连接酶配体。JQAD1以蛋白酶体依赖的方式导致神经母细胞瘤细胞系中EP300的降解。JQAD1抑制H3K27ac 和EP300的表达水平并诱导细胞凋亡。JQAD1抑制Kelly 细胞异种移植的NSG 小鼠的肿瘤生长。CRC 和MYCN 基因表达水平在JQAD1治疗的肿瘤中下调。JQAD1在诱导EP300降解的浓度下对共活化剂CBP 没有显著影响。 |
T29106 | VH032 | VH032通常用作 PROTAC 的前体,作为 E3泛素连接酶组件连接 VHL,是一种与 KdPROTACs 相互作用的 VHL/HIF-1α抑制剂,作为von Hippel-Lindau (VHL)的配体招募VHL 蛋白。 |
T5435 | ARV-771 | ARV-771 是基于 PROTAC 技术的有效 BET 降解剂,对 BRD2(1)、BRD2(2)、BRD3(1)、BRD3(2)、BRD4 (1) 和 BRD4(2)的 Kd 分别为 34、4.7、8.3、7.6、9.6 和 7.6 nM。 |
T17069 | THAL-SNS-032 | THAL-SNS-032 是一种选择性 CDK 降解剂,由 CereblonE3 连接酶 (CRBN) 的配体 thalidomide 衍生物、CDK 配体 SNS-032和 linker 组成的 PROTAC 连接体。 |
T61477 | dCeMM2 | dCeMM2 (Compound 2) 是一种胶降解剂。dCeMM2 促使 CDK12-cyclin K 与 CRL4B 连接酶复合物的相互作用,导致 cyclin K 的泛素化及降解。 |
T67778 | dCeMM1 | dCeMM1 是 RBM39 分子胶降解剂,可以降低 WT KBM7 细胞中 RBM39 水平的表达。dCeMM1 活性发挥通过重定向 CRL4DCAF15 连接酶进行。 |
T5440 | Dbet57 | dBET57 是基于 PROTAC 技术的 BRD4 异双功能降解剂,对 BRD4BD1 有显著降解作用,DC50/5h 为 500 nM。 |
T10526 | β-NF-JQ1 | β-NF-JQ1是一种PROTAC,可将芳烃受体E3 (AhR E3) 连接酶招募到目标蛋白上。β-NF-JQ1使用β-NF 作为AhR 配体靶向含溴odomain(BRD)的蛋白,诱导AhR 和BRD 蛋白相互作用。β-NF-JQ1显示出与蛋白敲除活性相关的强大的抗癌活性 。 |
T31221L | dBRD9 HCl | dBRD9 HCl 是一种PROTAC,包含cereblon E3连接酶配体与BRD9抑制剂BI 7273。dBRD9 HCl 是有效和选择性的BRD9降解剂,在MOLM-13细胞中IC50的为56.6nM。dBRD9 HCl 在浓度高达5μM 时不会降解BRD4或BRD7。dBRD9 HCl 在人AML 细胞系中显示出抗增殖作用。 |